Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: Finlabo SIM Spa

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA announces favorable Phase II study results for investigational Clostridium difficile Vaccine

Monday, 19 May 2014 08:01am EDT 

Sanofi SA:Says its Sanofi Pasteur, the vaccines division presented Phase II trial (H-030-012) results for an investigational vaccine for the prevention of Clostridium difficile.The Phase II trial met its primary objectives, reactions were generally mild and of short duration, and the candidate vaccine generated an immune response against C. diff toxins A and B. 

Company Quote

1.75 +2.43%
31 Oct 2014